Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 9/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865338 | 1.00 | ALDH1A1 (0.47) | ALDH1A1LMNASLC6A5MAPTUSP2 | |
| SCHEMBL1937084 | 0.85 | CTSK (0.46) | ALDH1A1SMN1; SMN2TGM2 | |
| SCHEMBL1445653 | 0.85 | SMN1; SMN2 (0.44) | ALDH1A1LMNASLC6A5MAPTUSP2 | |
| SCHEMBL330004 | 0.85 | CTSK (0.46) | ALDH1A1SMN1; SMN2TGM2 | |
| SCHEMBL1937079 | 0.85 | CTSK (0.46) | ALDH1A1SMN1; SMN2TGM2 | |
| SCHEMBL330005 | 0.85 | CTSK (0.46) | ALDH1A1SMN1; SMN2TGM2 | |
| SCHEMBL3683654 | 0.85 | CTSK (0.46) | ALDH1A1SMN1; SMN2TGM2 | |
| SCHEMBL2458918 | 0.85 | TGM2 (0.42) | ALDH1A1LMNASLC6A5MAPTUSP2 | |
| SCHEMBL2891734 | 0.85 | TGM2 (0.42) | ALDH1A1LMNASLC6A5MAPTUSP2 | |
| SCHEMBL2458923 | 0.85 | TGM2 (0.42) | ALDH1A1LMNASLC6A5MAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933110-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8785487-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2013052362-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-2528436-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| WO-2011091417-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | ALDH1A1 901/4885LMNA 886/4885SLC6A5 2473/4885 |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | ALDH1A1 984/4885LMNA 821/4885SLC6A5 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.